Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) Overview 6
Therapeutics Development 7
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Stage of Development 7
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Therapy Area 8
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Indication 9
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Companies 12
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Universities/Institutes 14
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Companies Involved in Therapeutics Development 22
Amgen Inc. 22
Ascendis Pharma A/S 23
Ono Pharmaceutical Co., Ltd. 24
Sanofi 25
Santen Pharmaceutical Co., Ltd. 26
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Drug Profiles 27
omidenepag isopropyl - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
ONO-8055 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
SAR-366234 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecule to Antagonize EP2 Receptor for Alzheimer's Disease - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
TG-4155 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
treprostinil - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Dormant Projects 34
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Discontinued Products 35
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Featured News & Press Releases 36
Apr 28, 2015: Ascendis Pharma A/S Announces Results of Phase 1 Study of TransCon Treprostinil 36
Jan 14, 2015: Ascendis Pharma Announces Initiation of a Phase 1 Single Ascending Dose Study of TransCon Treprostinil 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38

List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by Amgen Inc., H2 2016 22
Pipeline by Ascendis Pharma A/S, H2 2016 23
Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 24
Pipeline by Sanofi, H2 2016 25
Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 26
Dormant Projects, H2 2016 34
Discontinued Products, H2 2016 35

List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Mechanism of Actions, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 21